AAA
CNTA

Affinity Asset Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Affinity Asset Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$55.6M Buy
1,400,000
+799,448
+133% +$20.4M 2.87% 8
2025
Q4 		$15M Sell
600,552
-506,610
-46% -$12.8M 0.86% 36
2025
Q3 		$26.8M Buy
1,107,162
+207,000
+23% +$3.68M 2.34% 15
2025
Q2 		$11.8M Sell
900,162
-646,500
-42% -$8.19M 1.62% 20
2025
Q1 		$22.2M Buy
1,546,662
+450,738
+41% +$7.38M 2.12% 11
2024
Q4 		$18.4M Buy
1,095,924
+130,312
+13% +$2.16M 2.46% 13
2024
Q3 		$15.4M Sell
965,612
-170,090
-15% -$2.08M 2.11% 15
2024
Q2 		$10.3M Buy
1,135,702
+305,156
+37% +$2.89M 1.18% 23
2024
Q1 		$9.39M Buy
830,546
+34,817
+4% +$330K 1.16% 26
2023
Q4 		$6.33M Sell
795,729
-222,362
-22% -$1.49M 1.16% 25
2023
Q3 		$6.59M Buy
1,018,091
+117,368
+13% +$803K 1.85% 19
2023
Q2 		$5.58M Buy
900,723
+216,596
+32% +$1.03M 1.95% 17
2023
Q1 		$2.63M Buy
684,127
+223,799
+49% +$819K 0.87% 32
2022
Q4 		$1.43M Buy
460,328
+217,811
+90% +$807K 0.56% 46
2022
Q3 		$975K Buy
+242,517
New +$1.11M 0.27% 52
2022
Q2 		– Sell
-65,282
Closed -$586K – 58
2022
Q1 		$586K Sell
65,282
-353,862
-84% -$3.23M 0.09% 53
2021
Q4 		$4.72M Buy
419,144
+215,961
+106% +$2.91M 1.71% 25
2021
Q3 		$3.39M Buy
203,183
+136,226
+203% +$2.82M 0.86% 29
2021
Q2 		$1.49M Buy
+66,957
New +$1.57M 0.53% 43

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Affinity Asset Advisors's CNTA Position: Q1 2026 in Review

Affinity Asset Advisors increased its Centessa Pharmaceuticals (CNTA) stake by 133% in Q1 2026, buying an estimated $20.4M and bringing the position to 1,400,000 shares worth $55.6M. The position accounts for 2.87% of the portfolio, ranked #8.

Affinity Asset Advisors first reported a position in CNTA in Q2 2021 and has held it in 19 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Affinity Asset Advisors held 1,400,000 shares of Centessa Pharmaceuticals worth $55.6M as of Q1 2026.
  • Affinity Asset Advisors bought 799,448 Centessa Pharmaceuticals shares in Q1 2026, an estimated $20.4M.
  • Centessa Pharmaceuticals made up 2.87% of Affinity Asset Advisors's portfolio in Q1 2026, its #8 holding.
  • Affinity Asset Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 19 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.